Peroxisome proliferator-activated receptor gamma is frequently underexpressed in renal cell carcinoma

International Journal of Urology

Volumn 13, Issue 3, 2006, Pages 265-270

  Yuan, Jinyang ^a   Takahashi, Atsushi ^a   Masumori, Naoya ^a   Itoh, Naoki ^a   Tsukamoto, Taiji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Peroxisome proliferator activated receptor gamma; PPAR ; Renal cell carcinoma; Underexpression

Indexed keywords

MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY; KIDNEY CARCINOMA; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; PPAR GAMMA; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 33645459775     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01269.x     Document Type: Article

References (26)

1. Mangelsdorf DJ Thummel C Beato M et al. The nuclear receptor superfamily: the second decade. Cell 1995 83 835 9.
2. Desvergne B Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999 20 649 88.
3. Jiang C Ting AT Seed B. PPARγ; agonists inhibit production of monocyte inflammatory cytokines. Nature 1998 391 82 6.
4. Tontonoz P Nagy L Alvarez JG Thomazy VA Evans RM. PPARγ; promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998 93 241 52.
5. Spiegelman BM. PPARγ; in monocytes: less pain, any gain? Cell 1998 93 153 5.
6. Koeffler HP. Peroxisome proliferator-activated receptor γ; and cancers. Clin. Cancer Res. 2003 9 1 9.
7. Grommes C Landreth GE Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004 5 419 29.
8. Yuan J Takahashi A Masumori N et al. Ligands for peroxisome proliferator-Activated receptor gamma have a potent antitumor effect against human renal cell carcinoma. Urology 2005 65 594 9.
9. Terashita Y Sasaki H Haruki N et al. Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. Jpn. J. Clin. Oncol. 2002 32 238 43.
10. Sasaki H Tanahashi M Yukiue H et al. Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer 2002 36 71 6.
11. Aldred MA Morrison C Gimm O et al. Peroxisome proliferator-activated receptor γ; is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas. Oncogene 2003 22 3412 16.
12. Sarraf P Mueller E Smith WM et al. Loss-of-function mutations in PPARγ; associated with human colon cancer. Mol. Cell 1999 3 799 804.
13. Miyao N Tsukamoto T Kumamoto Y. Establishment of three human renal cell carcinoma cell lines (SMKT-R-1, SMKT-R-2, and SMKT-R-3) and their characters. Urol. Res. 1989 17 317 24.
14. Otani N Tsukamoto T Kumamoto Y Miyao N. Study on in vivo invasive potential of renal cell carcinoma cell lines and effect of growth factors (EGF and TGF-β1) on their in vivo invasions. Jpn. J. Urol. 1991 82 613 19.
15. Sobin LH Wittekind C. TNM Classification of Malignant Tumours 6th edn. Wiley-Liss New York 2002 193 5.
16. Pavan L Tarrade A Hermouet A et al. Human invasive trophoblasts transformed with simian virus 40 provide a new tool to study the role of PPARγ; in cell invasion process. Carcinogenesis 2003 24 1325 36.
17. 2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637. Int. J. Oncol. 2002 21 915 20.
18. DuBois RN Gupta R Brockman J Reddy BS Krakow SL Lazar MA. The nuclear eicosanoid receptor, PPARγ;, is aberrantly expressed in colonic cancers. Carcinogenesis 1998 19 49 53.
19. Motomura W Okumura T Takahashi N Obara T Kohgo Y. Activation of peroxisome proliferator-activated receptor γ; by troglitazone inhibits cell growth through the increase of p27KiP1 in human pancreatic carcinoma cells. Cancer Res. 2000 60 5558 64.
20. Inoue K Kawahito Y Tsubouchi Y et al. Expression of peroxisome proliferator-activated receptor γ; in renal cell carcinoma and growth inhibition by its agonists. Biochem. Biophys. Res. Commun. 2001 287 727 32.
21. Ikezoe T Miller CW Kawano S et al. Mutational analysis of the peroxisome proliferator-activated receptor γ; gene in human malignancies. Cancer Res. 2001 61 5307 10.
22. Shuin T Kondo K Torigoe S et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 1994 54 2852 5.
23. Jiang WG Douglas-Jones A Mansel RE. Expression of peroxisome-proliferator activated receptor-gamma (PPARγ;) and the PPARγ; co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int. J. Cancer 2003 106 752 7.
24. Marques AR Espadinha C Frias MJ et al. Underexpression of peroxisome proliferator-activated receptor (PPAR) γ; in PAX8/PPARγ;-negative thyroid tumours. Br. J. Cancer 2004 91 732 8.
25. Stetler-Stevenson WG Aznavoorian S Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 1993 9 541 73.
26. Ohta T Elnemr A Yamamoto M et al. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, modulates the E-cadherin/beta- catenin system in a human pancreatic cancer cell line, BxPC-3. Int. J. Oncol. 2002 21 37 42.